Cancers (Jun 2023)

CXC ELR-Positive Chemokines as Diagnostic and Prognostic Markers for Breast Cancer Patients

  • Joanna Motyka,
  • Aleksandra Kicman,
  • Monika Kulesza,
  • Sławomir Ławicki

DOI
https://doi.org/10.3390/cancers15123118
Journal volume & issue
Vol. 15, no. 12
p. 3118

Abstract

Read online

As the most common type of malignant lesison, breast cancer is a leading challenge for clinicians. Currently, diagnosis is based on self-examination and imaging studies that require confirmation by tissue biopsy. However, there are no easily accessible diagnostic tools that can serve as diagnostic and prognostic markers for breast cancer patients. One of the possible candidates for such markers is a group of chemokines that are closely implicated in each stage of tumorigenesis. Many researchers have noted the potential of this molecule group to become tumor markers and have tried to establish their clinical utility. In this work, we summarize the results obtained by scientists on the usefulness of the ELR-positive CXC group of chemokines in ancillary diagnosis of breast cancer.

Keywords